Modern Treatment of Amyloidosis: Unresolved Questions

被引：12

作者：

Dember, Laura M. ^{[1
]}

机构：

[1] Boston Univ, Sch Med, Renal Sect, Boston, MA 02118 USA

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 20卷 / 03期

关键词：

STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; SYSTEMIC AL AMYLOIDOSIS; LIGHT-CHAIN AMYLOIDOSIS; AA AMYLOIDOSIS; DEXAMETHASONE; SURVIVAL; POLYNEUROPATHY; ASSOCIATION; PROTEINURIA;

D O I：

10.1681/ASN.2008070793

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

During the past 10 to 15 years, there has been substantial progress in developing new treatments for the systemic amyloidoses. These advances have improved patient outcomes but have also raised new questions with direct clinical implications. For example, development of less intensive treatments for AL amyloidosis has made less certain the role of autologous stem cell transplantation, and new quantitative assays should now allow determination of the importance of fully eliminating amyloidogenic light chain production in AL disease. Additionally, observations from a clinical trial in AA amyloidosis have generated hypotheses about the relative contributions of amyloid precursors and mature fibrils to amyloidosis-associated kidney disease.

引用

页码：469 / 472

页数：4

共 42 条

[1] Quantitative analysis of serum free light chains - A new marker for the diagnostic evaluation of primary systemic amyloidosis [J].

Abraham, RS ;

Katzmann, JA ;

Clark, RJ ;

Bradwell, AR ;

Kyle, RA ;

Gertz, MA .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (02) :274-278

[2] Treatment of multiple myeloma [J].

Barlogie, B ;

Shaughnessy, J ;

Tricot, G ;

Jacobson, J ;

Zangari, M ;

Anaissie, E ;

Walker, R ;

Crowley, J .

BLOOD, 2004, 103 (01) :20-32

[3] Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress [J].

Brenner, DA ;

Jain, M ;

Pimentel, DR ;

Wang, B ;

Connors, LH ;

Skinner, M ;

Apstein, CS ;

Liao, RL .

CIRCULATION RESEARCH, 2004, 94 (08) :1008-1010

[4] Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis:: results of a phase II trial [J].

Cohen, Adam D. ;

Zhou, Ping ;

Chou, Joanne ;

Teruya-Feldstein, Julie ;

Reich, Lilian ;

Hassoun, Hani ;

Levine, Beth ;

Filippa, Daniel A. ;

Riedel, Elyn ;

Kewalramani, Tarun ;

Stubblefield, Michael D. ;

Fleisher, Martin ;

Nimer, Stephen ;

Comenzo, Raymond L. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (02) :224-233

[5]

Comenzo RL, 2008, NEW ENGL J MED, V358, P92

[6]

Comenzo RL, 1998, BLOOD, V91, P3662

[7] Eprodisate for the treatment of renal disease in AA amyloidosis [J].

Dember, Laura M. ;

Hawkins, Philip N. ;

Hazenberg, Bouke P. C. ;

Gorevic, Peter D. ;

Merlini, Giampaolo ;

Butrimiene, Irena ;

Livneh, Avi ;

Lesnyak, Olga ;

Puechal, Xavier ;

Lachmann, Helen J. ;

Obici, Laura ;

Balshaw, Robert ;

Garceau, Denis ;

Hauck, Wendy ;

Skinner, Martha .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (23) :2349-2360

[8] Amyloidosis-associated kidney disease [J].

Dember, Laura M. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (12) :3458-3471

[9] Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease [J].

Dember, LM ;

Sanchorawala, V ;

Seldin, DC ;

Wright, DG ;

LaValley, M ;

Berk, JL ;

Falk, RH ;

Skinner, M .

ANNALS OF INTERNAL MEDICINE, 2001, 134 (09) :746-753

[10] Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study [J].

Dispenzieri, A ;

Kyle, RA ;

Lacy, MQ ;

Therneau, TM ;

Larson, DR ;

Plevak, MF ;

Rajkumar, SV ;

Fonseca, R ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Zeldenrust, SR ;

Snow, DS ;

Hayman, SR ;

Litzow, MR ;

Gastineau, DA ;

Tefferi, A ;

Inwards, DJ ;

Micallef, IN ;

Ansell, SM ;

Porrata, LF ;

Elliott, MA ;

Gertz, MA .

BLOOD, 2004, 103 (10) :3960-3963

← 1 2 3 4 5 →